Bexotegrast治疗特发性肺纤维化:INTEGRIS-IPF临床试验
INTEGRIS-IPF是一项2a期多中心临床试验,将特发性肺纤维化(IPF)患者随机分配至每日口服Bexotegrast 40mg、80mg、160mg或320mg或安慰剂组,疗程至少12周。主要终点为治疗中出现的不良事件(TEAE)发生率,Bexotegrast汇总组与安慰剂组相似(69.7% vs 67.7%)。探索性分析显示Bexotegrast组FVC下降减少,定量肺纤维化(QLF)成像呈剂量依赖性抗纤维化效应,纤维化相关生物标志物下降。
要点
- Bexotegrast在IPF患者中耐受性良好,TEAE发生率与安慰剂相似。
- 探索性分析提示Bexotegrast可减少12周内FVC下降。
- QLF成像显示剂量依赖性抗纤维化效应,纤维化生物标志物下降。
核心结论
- Bexotegrast在 studied doses 下至12周表现出良好的安全性和耐受性。
- 探索性分析根据FVC、QLF成像和循环纤维化生物标志物提示抗纤维化效应。
研究设计与样本
- 2a期多中心临床试验,随机分配IPF患者接受每日口服Bexotegrast 40mg、80mg、160mg或320mg或安慰剂,每个剂量队列约3:1比例,疗程至少12周,可联合或不联合背景IPF治疗(吡非尼酮或尼达尼布)。
- 主要终点为治疗中出现的不良事件(TEAE)发生率。
主要发现
- Bexotegrast汇总组与安慰剂组TEAE发生率相似:62/89(69.7%) vs 21/31(67.7%)。
- 腹泻是最常见的TEAE,大多数腹泻患者也接受尼达尼布治疗。
- 与安慰剂相比,Bexotegrast组12周内FVC下降减少,无论是否联合背景治疗。
- QLF成像观察到Bexotegrast剂量依赖性抗纤维化效应。
- 与安慰剂相比,Bexotegrast组纤维化相关生物标志物下降。
临床怎么用
- Bexotegrast可能为IPF患者提供一种口服抗纤维化治疗选择,但需进一步验证。
- 治疗期间应关注腹泻等不良事件,尤其联合尼达尼布时。
局限性
- 本研究为2a期探索性试验,样本量有限,疗效终点为探索性。
- 研究持续时间较短(至少12周),长期安全性和有效性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).
引用
- Lancaster L, Cottin V, Ramaswamy M, et al. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. Am J Respir Crit Care Med. 2024. PMID: 38843105. doi:10.1164/rccm.202403-0636OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。